Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc.

Bank of America Securities analyst Travis Steed reiterated a Hold rating on Baxter International today and set a price target of $24.00. Steed cove...

Baxter International (BAX) Gets a Hold from Bank of America Securities

Barclays analyst Flora Bocahut maintained a Buy rating on Julius Baer Group Ltd on May 26 and set a price target of CHF73.00. According to TipRanks...

Barclays Keeps Their Buy Rating on Julius Baer Group Ltd (BAER)

In a report released today, Giulia Miotto from Morgan Stanley maintained a Sell rating on Julius Baer Group Ltd, with a price target of CHF62.00. A...

Morgan Stanley Sticks to Its Sell Rating for Julius Baer Group Ltd (BAER)

Barclays analyst Flora Bocahut maintained a Buy rating on Julius Baer Group Ltd on May 22 and set a price target of CHF73.00. The company’s shares ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BAX	$19.89	+2.58%	11.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BAX	$19.89	+2.6%	11.17M
3
4
5
6

BAX

BAX

Recent News for BAX

Get Baxter International Inc. Data in Excel

Get Baxter International Inc. Data in Excel